FibroGen Statistics

Total Valuation

FibroGen has a market cap or net worth of MXN 619.74 million. The enterprise value is -544.52 million.

Market Cap	619.74M
Enterprise Value	-544.52M

Important Dates

The next estimated earnings date is Monday, February 23, 2026.

Earnings Date	Feb 23, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	4.05M
Shares Outstanding	n/a
Shares Change (YoY)	+1.55%
Shares Change (QoQ)	+0.05%
Owned by Insiders (%)	2.06%
Owned by Institutions (%)	16.35%
Float	3.58M

Valuation Ratios

The trailing PE ratio is 0.16.

PE Ratio	0.16
Forward PE	n/a
PS Ratio	4.07
PB Ratio	1.93
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.14
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	1.74

Financial Position

The company has a current ratio of 3.71, with a Debt / Equity ratio of 1.11.

Current Ratio	3.71
Quick Ratio	3.56
Debt / Equity	1.11
Debt / EBITDA	n/a
Debt / FCF	-1.14
Interest Coverage	-6.91

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-18.42%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-58.55%
Revenue Per Employee	676,460
Profits Per Employee	17.58M
Employee Count	225
Asset Turnover	0.04
Inventory Turnover	2.78

Taxes

Income Tax	-1.61M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -27.67% in the last 52 weeks. The beta is 0.74, so FibroGen's price volatility has been lower than the market average.

Beta (5Y)	0.74
52-Week Price Change	-27.67%
50-Day Moving Average	167.16
200-Day Moving Average	294.93
Relative Strength Index (RSI)	37.91
Average Volume (20 Days)	435

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	4.76

Income Statement

In the last 12 months, FibroGen had revenue of MXN 152.20 million and earned 3.96 billion in profits. Earnings per share was 979.10.

Revenue	152.20M
Gross Profit	-556.70M
Operating Income	-1.09B
Pretax Income	-960.16M
Net Income	3.96B
EBITDA	-1.07B
EBIT	-1.09B
Earnings Per Share (EPS)	979.10

Full Income Statement

Balance Sheet

The company has 2.16 billion in cash and 357.14 million in debt, giving a net cash position of 1.81 billion.

Cash & Cash Equivalents	2.16B
Total Debt	357.14M
Net Cash	1.81B
Net Cash Per Share	n/a
Equity (Book Value)	320.71M
Book Value Per Share	-77.21
Working Capital	1.79B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -310.20 million and capital expenditures -3.28 million, giving a free cash flow of -313.49 million.

Operating Cash Flow	-310.20M
Capital Expenditures	-3.28M
Free Cash Flow	-313.49M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-712.89%
Pretax Margin	-630.84%
Profit Margin	2,598.87%
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

FibroGen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.55%
Shareholder Yield	-1.55%
Earnings Yield	638.26%
FCF Yield	-50.58%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

The last stock split was on June 17, 2025. It was a reverse split with a ratio of 0.04.

Last Split Date	Jun 17, 2025
Split Type	Reverse
Split Ratio	0.04

Scores

FibroGen has an Altman Z-Score of -17.61 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-17.61
Piotroski F-Score	3